Ventilator associated pneumonia (VAP) is an intensive care unit (ICU) for acquired infection. This pulmonary infection generally occurs 48 hours after a patient is incubated and has received mechanical ventilation. Incidence of VAP ranges from 6% to 55% and can reach up to 76% in some situations. VAP is a major cause of illness and death. Patients suffering with VAP have increased spans of ICU hospitalization. Moreover, death rate has risen to 20% to 30%. The incidence rate of VAP depends on many factors including reintubation, age & altered consciousness, duration of mechanical ventilation, and supine position. Early and precise diagnosis of VAP is tough and there is an urgent need of an optimal antibiotic treatment. Diagnosis of VAP requires high clinical suspicion in combination with bedside examination, microbiologic analysis of respiratory secretions, and radiographic examination. A composite clinical score named clinical pulmonary infection score (CPIS) is derived by observing these. CPIS is based on six criteria: blood leukocyte count, temperature, oxygenation, volume & purulence of tracheal secretions, semiquantitative culture of tracheal aspirate, and pulmonary radiography. Based on these, the treatment of patients suffering from VAP is planned. Precise treatment of VAP is decided after exact causative bacteria of the disease is detected. On the other hand, when VAP is first is suspected, and if the bacteria causing the infection is specifically not known, then broad-spectrum of antibiotics (empiric therapy) are considered for the treatment, until exact cause of disease (particular bacteria) is determined.
The global ventilator-associated pneumonia (VAP) market is anticipated to grow rapidly in the near future. Major factors driving the market are rise in geriatric population, increase in hospital acquired in infections, and global rise in respiratory infections. One of the important elements affecting helping growth of hospital acquired infections is, ICU patients have prevailing underlying factors which relates to immunodeficiency for example glucocorticoid therapy or diabetes mellitus. These elements increase the risk of ventilator associated pneumonia (VAP). Other factors fueling the growth of the global ventilator associated pneumonia (VAP) market are rise in investments in health care, reimbursement policies in developed nations of North America and Europe, and advancements in technologies. However, high cost of overall treatment, side effects related to treatments, and lack of reimbursement policies in emerging countries are likely to restrain the market.
The global ventilator-associated pneumonia (VAP) market has been segmented based on diagnosis, mode of treatment, and end-user. In terms of diagnosis, the market has been segmented into radiological, microbiological, clinical, and others. Based on mode of treatment, the global ventilator-associated pneumonia (VAP) market has been divided into home care, hospital care, and others. In terms of end-user, the VAP market consists of hospitals, clinics, research facilities, and others.
Geographically the global ventilator-associated pneumonia (VAP) market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America leads the global market due to better awareness among people about early diagnosis of diseases and rise in the number of respiratory & related infectious diseases. Favorable reimbursement policies and wide acceptance of advanced technologies are the other factors attributed to North America’s dominance of the global market. Europe is also projected to grow quickly, as top players in the market are cooperating with research institutions & labs to develop new innovative products. The market in Asia Pacific is projected to expand at a high growth rate due to increase in disposable income, unmet needs of the rising population, swiftly evolving health care network, improved reimbursement facilities, and health care awareness.
Key players in the VAP market are Merck & Co., Inc., Adenium Biotech ApS (Denmark), AstraZeneca, MedImmune, Nabriva Therapeutics AG, and Thermo Fisher Scientific.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.